Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 5170.4.

https://doi.org/10.1182/blood-2024-211018

Published: 2024

Journal Articles

Use of Doublet Maintenance (Bortezomib-Lenalidomide) Vs Monotherapy Lenalidomide As Maintenance Therapy Post-Transplant of Patients with High-Risk Cytogenetics Myeloma

Mehak M Laharwal, Jordan Snyder, Aroog Khaliq, Raeef L Rahman, Shebli Atrash, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla

Blood (2024) 144 (Supplement 1): 7017.

https://doi.org/10.1182/blood-2024-201907

Published: 2024

Journal Articles

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7860.

https://doi.org/10.1182/blood-2024-210976

Published: 2024

Journal Articles

Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients

Raeef L Rahman, Aroog Khaliq, Mehak M Laharwal, Shebli Atrash, Joseph P. McGuirk, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla, Jordan Snyder

Blood (2024) 144 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2024-206098

Published: 2024

Journal Articles

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

Priyanka Venkatesh, Raeef L Rahman, Aroog Khaliq, Mehak M Laharwal, Shebli Atrash, Joseph P. McGuirk, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla, Jordan Snyder, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 6943.

https://doi.org/10.1182/blood-2024-211572

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Abdullah Mohammad Khan, Mehak M Laharwal, Prerna Mewawalla, Marshall McKenna, Yun Kyoung Tiger, Hira Shaikh, Christopher Strouse, Kimberly M Green, James A Davis, Hamza Hashmi, Jordan Snyder, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Barry Paul, Reed Friend

Blood (2024) 144 (Supplement 1): 7037.

https://doi.org/10.1182/blood-2024-209283

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Jordan Snyder, Chelsea Gorsline, Dilek Ince, Aneela Majeed, Faiz Anwer, Hira Shaikh, Abdullah Mohammad Khan, Al-Ola Abdallah, Kimberly M Green, Shebli Atrash, Claire Yun Kyoung Ryu Tiger, Prerna Mewawalla, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2024-208349

Published: 2024

Journal Articles

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Blood (2024) 144 (Supplement 1): 3760.

https://doi.org/10.1182/blood-2024-201712

Published: 2024

Journal Articles

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2411.7.

https://doi.org/10.1182/blood-2024-204158

Published: 2024

Journal Articles

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Rachel Dileo, Prerna Mewawalla, Gina Patrus, Christopher Strouse, Ethan Chen, Hira Shaikh, James A Davis, Kimberly M Green, Omar Alkharabsheh, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Blood (2024) 144 (Supplement 1): 4742.

https://doi.org/10.1182/blood-2024-206059

Published: 2024

Journal Articles

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Urwat Til Vusqa, Palash Asawa, Maitreyee Rai, Yazan Samhouri, Prerna Mewawalla, Anna Koget, Santhosh Sadashiv, Cyrus Kahn, Salman Fazal, John Lister

Blood (2021) 138 (Supplement 1): 4816.

https://doi.org/10.1182/blood-2021-151113

Published: 2021

Journal Articles

Hemophagocytic Lymphohistiocytosis with Hodgkin's Lymphoma, HIV and EBV: Which One to Blame As the Trigger?

Hira G. Shaikh, MD, Amir Kamran, MD, Prerna Mewawalla, MD

Blood (2017) 130 (Supplement 1): 4817.

https://doi.org/10.1182/blood.V130.Suppl_1.4817.4817

Published: 2017

Journal Articles

Propylthiouracil: A Well Known Cause of Agranulocytosis, but Can It Cause Aplastic Anemia?

Hira G. Shaikh, MD, Amir Kamran, MD, Prerna Mewawalla, MD

Blood (2017) 130 (Supplement 1): 4959.

https://doi.org/10.1182/blood.V130.Suppl_1.4959.4959

Published: 2017

Journal Articles

Serum Free Light Chain Concentration (>1000mg/dl) at Diagnosis and at Relapse Predicts for Very Poor Prognosis in Multiple Myeloma

Abhishek Chilkulwar, MD, Prerna Mewawalla, MD, Anna Miller, Gina Berteotti, Entezam Sahovic, MD, John Lister, MD

Blood (2016) 128 (22): 5698.

https://doi.org/10.1182/blood.V128.22.5698.5698

Published: 2016

NARROW

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Use of Doublet Maintenance (Bortezomib-Lenalidomide) Vs Monotherapy Lenalidomide As Maintenance Therapy Post-Transplant of Patients with High-Risk Cytogenetics Myeloma

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Safety and Efficacy of Belantamab Mafadotin in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Hemophagocytic Lymphohistiocytosis with Hodgkin's Lymphoma, HIV and EBV: Which One to Blame As the Trigger?

Propylthiouracil: A Well Known Cause of Agranulocytosis, but Can It Cause Aplastic Anemia?

Serum Free Light Chain Concentration (>1000mg/dl) at Diagnosis and at Relapse Predicts for Very Poor Prognosis in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only